References

Multiple myeloma

10.1056/nejmra1011442 · 2011 · External reference

Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival

10.1111/ejh.13083 · 2018 · External reference

Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma

10.1073/pnas.97.1.228 · 2000 · External reference

The multiple mechanism of MCL1 in the regulation of cell fate

10.1038/s42003-021-02564-6 · 2021 · External reference

First-in-human dose-escalation study of cyclin-dependent kinase 9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy

10.1158/1078-0432.ccr-21-3617 · 2022 · External reference

Enitociclib, a selective CDK9 inhibitor, induces complete regression of MYC+ lymphoma by downregulation of RNA polymerase II mediated transcription

10.1158/2767-9764.crc-23-0219 · 2023 · External reference

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples

10.1093/nar/gkac382 · 2022 · External reference

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia

10.1038/s41375-022-01758-z · 2023 · External reference

Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients

10.4081/ejh.2011.e21 · 2011 · External reference

Bortezomib (VelcadeTM) in the treatment of multiple myeloma

10.2147/tcrm.2006.2.3.271 · 2006 · External reference

IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact

2023 · External reference

ETV4-dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma

10.1158/2643-3230.bcd-23-0061 · 2024 · External reference

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma

10.1038/bcj.2013.38 · 2013 · External reference

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

10.1182/blood-2017-06-788786 · 2017 · External reference

Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies

2018 · External reference

Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies

10.1016/j.ccell.2019.08.005 · 2019 · External reference

Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells

10.1038/s41375-022-01553-w · 2022 · External reference

Ubiquitin-independent degradation of antiapoptotic MCL-1

10.1128/mcb.01266-09 · 2010 · External reference

c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt’s lymphoma cells

10.1128/mcb.20.7.2423-2435.2000 · 2000 · External reference

Changing for the better: discovery of the highly potent and selective CDK9 inhibitor VIP152 suitable for once weekly intravenous dosing for the treatment of cancer

10.1021/acs.jmedchem.1c01000 · 2021 · External reference

Chromosome 1q21 abnormalities in multiple myeloma

10.1038/s41408-021-00474-8 · 2021 · External reference

Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents

10.1007/s12185-020-03005-6 · 2021 · External reference

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma

10.1038/s41408-022-00610-y · 2022 · External reference

Prognostic and predictive biomarker developments in multiple myeloma

10.1186/s13045-021-01162-7 · 2021 · External reference